Skip to content
DataLookout
Menu

NCT07938580

Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants Achieving an Anemia Response
Timeframe: 24 week

Secondary (12)

Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Time to Anemia Response
Duration of Anemia Response
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Change From Baseline in Hemoglobin
Show 7 moreShow less
SVR35
DoMSR
MPN-SAF TSS
Reduction in Fatigue Score
Adverse Events
PFS
OS

Arms and interventions

Gecacitinib + LuspaterceptExperimental

gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks

Drugs: Gecacitinib, Luspatercept